Gilead submits Truvada/rilpivirine NDA

Gilead Sciences Inc. (NASDAQ:GILD) submitted an NDA to FDA for a fixed-dose combination of rilpivirine and Truvada emtricitabine/tenofovir to treat HIV infection in adults. Johnson & Johnson (NYSE:JNJ) partnered with Gilead last year to develop the combination of J&J's rilpivirine ( TMC278) and Gilead's Truvada. In September, Gilead submitted an MAA to EMA for the combination. ...